News >

PARP Inhibition Improves PFS as Frontline Maintenance in Ovarian Cancer, OS Data Awaited

Kristi Rosa
Published: Tuesday, Aug 20, 2019

Lan G. Coffman, MD, PhD, assistant professor at the University of Pittsburgh Medical Center Hillman Cancer Center

Lan G. Coffman, MD, PhD

Frontline maintenance PARP inhibition has led to impressive progression-free survival (PFS) benefit in patients with advanced ovarian cancer, said Lan G. Coffman, MD, PhD, but the hope is that treatment with these agents will also translate to an extension in overall survival (OS).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Publication Bottom Border
Border Publication
x